Thesis
Eli Lilly's $1.2B all-cash acquisition of Ventyx closed March 2026, returning capital to shareholders at a 62% premium — no remaining public investment thesis exists
Ventyx Biosciences was acquired by Eli Lilly in a completed $1.2 billion all-cash transaction at $14.00 per share, closing March 4, 2026. No publicly traded equity or active pipeline programs remain — the company no longer exists as an investable entity. The acquisition resolves all prior thesis questions; there is no residual risk or upside for public shareholders.
Focus
Eli Lilly $1.2B all-cash acquisition of Ventyx Biosciences closed March 2026
2026-03-04
Bull
The transaction closed at the full agreed price of $14.00 per share with no reduction, delivering the 62% premium to pre-announcement VWAP to all shareholders; Lilly absorbs VTX2735 (IL-18 inhibitor) and VTX3232 into a deep-pocketed development engine that can accelerate trials without capital constraints faced by a small-cap biotech.
Bear
As a wholly owned Lilly subsidiary, Ventyx's pipeline programs could be deprioritized or discontinued if they conflict with Lilly's internal immunology or metabolic portfolio, and former public shareholders have no ongoing economic interest or visibility into program outcomes post-close.
Unlock the full thesis for VTYX.
The living thesis log, full pipeline, competitive landscape, and the ability to ask anything — updated automatically as the story changes.
Start your 7-day free trialRelated companies
Generated automatically from SEC filings, trial readouts, and earnings calls. For informational purposes only. Not financial advice.